The Effect of T-Cell Transcription Factors on the Immunopathogenesis of Rheumatoid Arthritis
DOI:
https://doi.org/10.71222/f08rw834Keywords:
T-cell transcription factor, rheumatoid arthritis, immunopathogenesisAbstract
Objective: This looks at investigates the impact of T-cell transcription factors at the immunopathogenesis of rheumatoid arthritis (RA). Methods: An overall of 60 sufferers diagnosed with RA and handled in our health center between January 2022 and January 2024 had been selected because the remark organization, whilst 60 healthy those who underwent routine health test-usual through the equal length had been distinct as the manipulate group. Peripheral blood samples from each organization were analyzed to measure the proportion and proliferative interest of regulatory T cells (Tregs), as well as their inhibitory feature on effector T cells. Levels of the T-cell transcription component STAT3 and associated inflammatory factors were additionally tested. RA patients had been handled with a STAT3 inhibitor to take a look at changes in Treg proliferation, inhibitory function, and the secretion stages of seasoned-inflammatory factors. Additionally, synovial tissue from RA patients changed into received for histopathological evaluation the usage of mild microscopy to assess synovial infection and hyperplasia. Results: The peripheral blood of the remark organization confirmed substantially decrease Treg counts compared to the manipulate group (P < 0.05). The in vitro proliferation charge of Tregs in the remark group was additionally decrease than within the manipulate group (P < 0.05). Levels of p-STAT3, TNF-α, IFN-γ, and IL-17A in Tregs have been higher within the commentary group, and the expression tiers of TNF-α, IFN-γ, and IL-17A mRNA have been also improved in comparison to the manage group (P < 0.05). RA sufferers handled with 50 μg/L STAT3 inhibitor confirmed a substantially better Tresp suppression price in comparison to untreated sufferers (P < 0.05). However, there has been no statistically tremendous distinction in Treg proliferation charges among the treated institution and the control institution (P > 0.05). The expression of p-STAT3 protein in Tregs became lower in the treated group compared to untreated sufferers (P < 0.05), and not using a big difference as compared to the manage organization (P > 0.05). Similarly, TNF-α, IFN-γ, and IL-17A mRNA stages had been reduced in the dealt with organization compared to untreated sufferers (P < 0.05), but no great distinction turned into found whilst in comparison to the manage group (P > 0.05). Histopathological evaluation discovered mentioned inflammatory responses in the synovial tissue of the statement organization, inclusive of congestion and edema of the synovial stroma, full-size lymphocyte and plasma cellular infiltration, focal necrosis, epithelial hyperplasia, fibrinous exudation, and necrotic particles accumulation. Conclusion: RA patients show off synovial inflammation and hyperplasia, together with a lack of ability to efficiently suppress Tresp cells thru Tregs. The mechanism is intently related to peculiar STAT3 expression. Inhibiting aberrant STAT3 expression extensively influences the immunopathogenesis of RA, probably restoring Treg feature, assuaging seasoned-inflammatory thing secretion, and preventing the development of RA.
References
1. Hosokawa, H., & Rothenberg, E. V., “How transcription factors drive choice of the T cell fate,” Nat. Rev. Immunol., vol. 21, no. 3, pp. 162–176, Mar. 2021, doi: 10.1038/s41577-020-00426-6.
2. Trujillo-Ochoa, J. L., Kazazian, M., & Afzali, B., “The role of transcription factors in shaping regulatory T cell identity,” Nat. Rev. Immunol., vol. 23, no. 12, pp. 842–856, Dec. 2023, doi: 10.1038/s41577-023-00893-7.
3. Ono, M., “Control of regulatory T‐cell differentiation and function by T‐cell receptor signaling and Foxp3 transcription factor complexes,” Immunology, vol. 160, no. 1, pp. 24–37, Jan. 2020, doi: 10.1111/imm.13178.
4. Rothenberg, E. V., “Logic and lineage impact on functional transcription factor deployment for T-cell fate commitment,” Bi-opsy’s. J., vol. 120, no. 19, pp. 4162–4181, May 2021, doi: 10.1016/j.bpj.2021.04.002.
5. Ji, L. S., et al., “Mechanism of follicular helper T cell differentiation regulated by transcription factors,” J. Immunol. Res., vol. 2020, pp. 1826587, Dec. 2020, doi: 10.1155/2020/1826587.
6. Dhime, K., Kaye, B., & McKinstry, K. K., “Regulation of CD4 T cell responses by the transcription factor hemosiderin,” Bio-molecules, vol. 12, no. 11, pp. 1549, Nov. 2022, doi: 10.3390/biom12111549.
7. Katagiri, T., et al., “Regulation of T cell differentiation by the AP-1 transcription factor Jun,” Immunol. Med., vol. 44, no. 3, pp. 197–203, Jul. 2021, doi: 10.1080/25785826.2021.1872838.
8. van der Veer Ken, J., et al., “The transcription factor Foxp3 shapes regulatory T cell identity by tuning the activity of trans-acting intermediaries,” Immunity, vol. 53, no. 5, pp. 971–984, Nov. 2020, doi: 10.1016/j.immuni.2020.10.010.
9. Lukhele, S., et al., “The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity,” Immunity, vol. 55, no. 12, pp. 2369–2385, Dec. 2022, doi: 10.1016/j.immuni.2022.10.020.
10. Nixon, B. G., et al., “Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer,” Immunity, vol. 55, no. 11, pp. 2044–2058, Nov. 2022, doi: 10.1016/j.immuni.2022.10.002.
11. Lu, H., et al., “Overexpression of early T cell differentiation-specific transcription factors transforms the terminally differenti-ated effector T cells into less differentiated state,” Cell. Immunol., vol. 353, pp. 104118, Aug. 2020, doi: 10.1016/j.cellimm.2020.104118.
12. Leng, F., et al., “The transcription factor FoxP3 can fold into two dimerization states with divergent implications for regula-tory T cell function and immune homeostasis,” Immunity, vol. 55, no. 8, pp. 1354–1369, Oct. 2022, doi: 10.1016/j.immuni.2022.07.002.
13. [13] Goldman, N., et al., “Intrinsically disordered domain of transcription factor TCF-1 is required for T cell developmental fidelity,” Nat. Immunol., vol. 24, no. 10, pp. 1698–1710, Oct. 2023, doi: 10.1038/s41590-023-01599-7.
14. Malakar, B., “Co-expression of master transcription factors determines CD4+ T cell plasticity and functions in au-to-inflammatory diseases,” Immunol. Lett., vol. 222, pp. 58–66, Jun. 2020, doi: 10.1016/j.imlet.2020.03.007.
15. Neshan, M., et al., “Alterations in T-Cell transcription factors and cytokine gene expression in late-onset Alzheimer’s Disease,” J. Alzheimer’s Dis., vol. 85, no. 2, pp. 645–665, Jul. 2022, doi: 10.3233/JAD-210480.
16. Read, K. A., et al., “Aiolos represses CD4+ T cell cytotoxic programming via reciprocal regulation of TFH transcription factors and IL-2 sensitivity,” Nat. Common., vol. 14, no. 1, pp. 1652, Jan. 2023, doi: 10.1038/s41467-023-37420-0.
17. Ribeiro, V. R., et al., “Immunomodulatory effect of vitamin D on the STATs and transcription factors of CD4+ T cell subsets in pregnant women with preeclampsia,” Clin. Immunol., vol. 234, pp. 108917, Aug. 2022, doi: 10.1016/j.clim.2021.108917.
18. Wilkens, A. B., et al., “NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness,” Blood, vol. 140, no. 21, pp. 2261–2275, Nov. 2022, doi: 10.1182/blood.2021015144.
19. Astore, A., et al., “ARID1a associates with lymphoid-restricted transcription factors and has an essential role in T cell devel-opment,” J. Immunol., vol. 205, no. 5, pp. 1419–1432, Sep. 2020, doi: 10.4049/jimmunol.1900959.
20. Sekiya, T., et al., “Essential roles of the transcription factor NR4A1 in regulatory T cell differentiation under the influence of immunosuppressants,” J. Immunol., vol. 208, no. 9, pp. 2122–2130, May 2022, doi: 10.4049/jimmunol.2100808.
21. Tile, L., et al., “Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion,” Nat. Immunol., vol. 24, no. 10, pp. 1645–1653, Oct. 2023, doi: 10.1038/s41590-023-01614-x.
22. Linskey, D., et al., “Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor,” Mol. Ther. Oncolytic., vol. 29, pp. 77–90, Jul. 2023, doi: 10.1016/j.omto.2023.04.005.
23. Ribeiro, V. R., et al., “Vitamin D modulates the transcription factors of T cell subsets to anti-inflammatory and regulatory profiles in preeclampsia,” Int. Immunopharmacology., vol. 101, pp. 108366, Nov. 2021, doi: 10.1016/j.intimp.2021.108366.
24. Zhao, X., Shan, Q., & Xue, H.-H., “TCF1 in T cell immunity: a broadened frontier,” Nat. Rev. Immunol., vol. 22, no. 3, pp. 147–157, Mar. 2022, doi: 10.1038/s41577-021-00563-6.
